At Alligator Biosience we focus on drug discovery and early development, and we highly acknowledge scientific collaborations with academia and co-development with biotechnology and pharmaceutical companies.
Alligator actively evaluates licensing and collaboration opportunities from academic researchers and biotech companies. Collaborations may be structured as in-licensing of IP and/or drug candidates or co-development with shared costs and future revenue.
In-licensing/collaboration opportunities of early stage protein-based drug candidates in cancer.
Novel target identification, IP related to target in cancer.